Related Experiment Videos
Growth hormone receptor antagonists.
1Edison Biotechnology Institute, Ohio University, Athens, Ohio 45701, USA. kopchick@edison.biotech.ohiou.ed
Minerva Endocrinologica
|January 4, 2003
Summary
Growth hormone (GH) regulates growth and differentiation. A GH receptor antagonist, pegvisomant, effectively treats acromegaly by blocking GH
Area of Science:
- Endocrinology
- Molecular Biology
- Physiology
Background:
- Growth hormone (GH) is crucial for vertebrate growth and cellular differentiation.
- GH levels exhibit sexual dimorphism and change throughout development and lifespan.
- Pituitary GH synthesis and secretion are tightly regulated, with abnormal levels causing pathologies like dwarfism or acromegaly.
Purpose of the Study:
- To provide an overview of the GH/insulin-like growth factor (IGF-1) axis.
- To highlight the therapeutic potential of GH receptor antagonists, specifically pegvisomant.
Main Methods:
- Review of existing literature on GH physiology and the GH/IGF-1 axis.
- Discussion of the mechanism of action of pegvisomant as a GH receptor antagonist.
- Exploration of clinical applications and therapeutic implications of pegvisomant.
Main Results:
- Pegvisomant competes with endogenous GH for receptor binding.
- This antagonism leads to the suppression of serum IGF-1 levels.
- Pegvisomant is an established treatment for acromegaly.
Conclusions:
- The GH/IGF-1 axis is a key regulator of growth and metabolism.
- GH receptor antagonists like pegvisomant offer a targeted therapeutic strategy.
- Pegvisomant shows promise for treating acromegaly and potentially other conditions like cancer and diabetic end-organ damage.